-- Homi Shamir, President and CEO of Given Imaging
-- Prof. Rami Eliakim, Rambam Medical Center and Prof. Sam Adler, Bikkur
Holim Hospital, principal investigators from the PillCam COLON2 feasibility
trial who will review results
-- Prof. Jacques Devière, Erasme Hospital, Brussels will discuss the need
for alternatives to colonoscopy in Europe
If interested in attending the meeting in person, please call +212-867-1768
or email dcarey@lazarpartners.com. To participate in the teleconference,
please dial one of the following numbers ten minutes before the conference
is scheduled to begin:
-- U.S. participants: 1-888-219-1217
-- U.K. participants: 08081017548
-- All other international callers please dial +913-312-1463 and include
appropriate codes for dialing the U.S.
This meeting will also be webcast live at www.givenimaging.com. A replay of
the call will be available for two weeks on the company's website, or until
December 7, 2009 by dialing 888-203-1112. Callers outside of the U.S.
should dial 719-457-0820. The replay participant code is 8784603.
About PillCam COLON
PillCam COLON enables the physician to directly see the colon mucosa in its
natural state while not requiring sedation, intubation, air insufflation,
hospitalization or radiation. PillCam COLON is a smooth plastic capsule
which can be naturally ingested with a sip of water. It utilizes advanced
optical technology with tiny video cameras at each end, which produces
enhanced resolution images and includes automatic light control and a wide
field of view.
About Given Imaging Ltd.
Given Imaging has advanced gastrointestinal diagnosis by developing
innovative, patient-friendly tools based on its PillCam® Platform.
PillCam capsule endoscopy provides physicians with natural images of the
small intestine via PillCam® SB, the esophagus through PillCam® ESO,
and the colon with PillCam® COLON [PillCam COLON is not cleared for use
in the USA]. The PillCam capsules are miniature video cameras that patients
ingest. Given Imaging's other capsule products include Agile™ patency
capsule, to verify intestinal patency, and Bravo®, the only wireless,
catheter-free, 48-hour pH test commercially available for pH testing to
assess gastroesophageal reflux disease (GERD). Given Imaging's products use
cutting-edge, wireless technology and advanced software to enable
gastroenterologists to evaluate and detect abnormalities of the esophagus,
small bowel and colon and more accurately treat patients. All Given Imaging
products allow patients to maintain normal activities. Since 2001, more
than one million PillCam® video capsules have helped physicians evaluate
patients for GI disorders. Given Imaging's headquarters, manufacturing and
R&D facilities are located in Yoqneam, Israel, with operating subsidiaries
in the United States, Germany, France, Japan, Australia and Singapore. For
more information, please visit http://www.givenimaging.com.
This press release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but are not
limited to, projections about our business and our future revenues,
expenses and profitability. Forward-looking statements may be, but are not
necessarily, identified by the use of forward-looking terminology such as
"may," "anticipates," "estimates," "expects," "intends," "plans,"
"believes," and words and terms of similar substance. Forward-looking
statements involve known and unknown risks, uncertainties and other factors
which may cause the actual events, results, performance, circumstances or
achievements of the Company to be materially different from any future
events, results, performance, circumstances or achievements expressed or
implied by such forward-looking statements. Factors that could cause actual
events, results, performance, circumstances or achievements to differ from
such forward-looking statements include, but are not limited to, the
following: (1) our ability to develop and bring to market new products, (2)
our ability to receive regulatory clearance or approval to market our
products or changes in regulatory environment, (3) our success in
implementing our sales, marketing and manufacturing plans, (4) protection
and validity of patents and other intellectual property rights, (5) the
impact of currency exchange rates, (6) the effect of competition by other
companies, (7) the outcome of significant litigation, (8) our ability to
obtain reimbursement for our product from government and commercial payors,
(9) quarterly variations in operating results, (10) the possibility of
armed conflict or civil or military unrest in Israel, (11) the impact of
global economic conditions, and (12) other risks and factors disclosed in
our filings with the U.S. Securities and Exchange Commission, including,
but not limited to, risks and factors identified under such headings as
"Risk Factors," "Cautionary Language Regarding Forward-Looking Statements"
and "Operating Results and Financial Review and Prospects" in the Company's
Annual Report on Form 20-F for the year ended December 31, 2008. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. Except for the
Company's ongoing obligations to disclose material information under the
applicable securities laws, it undertakes no obligation to release publicly
any revisions to any forward-looking statements, to report events or to
report the occurrence of unanticipated events.
Contact Information: For further information contact: Fern Lazar/David Carey Lazar Partners Ltd. 212-867-1768 /